The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma

Abstract

WD repeat-containing protein 1 (WDR1) regulates the cofilin 1 (CFL1) activity, promotes cytoskeleton remodeling, and thus, facilitates cell migration and invasion. A previous study reported that autoantibodies against CFL1 and β-actin were useful biomarkers for diagnosing and predicting the prognosis of patients with esophageal carcinoma. Therefore, the present study aimed to evaluate the serum levels of anti-WDR1 antibodies (s-WDR1-Abs) combined with serum levels of anti-CFL1 antibodies (s-CFL1-Abs) in patients with esophageal carcinoma. Serum samples obtained from 192 patients with esophageal carcinoma and other solid cancers. And s-WDR1-Ab and s-CFL1-Ab titers were analyzed using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay. Compared with those of healthy donors, the s-WDR1-Ab levels were significantly higher in the 192 patients with esophageal, whereas these were not significantly higher in the samples from patients with gastric, colorectal, lung, or breast cancer. In 91 patients treated with surgery, sex, tumor depth, lymph node metastasis, stage and C-reactive protein levels were significantly associated with overall survival, as determined using the log-rank test, whereas the squamous cell carcinoma antigen, p53 antibody and s-WDR1-Ab levels tended to be associated with a worse prognosis. Although no significant difference was observed in the survival between the positive and negative groups of s-WDR1-Abs or s-CFL1-Abs alone in the Kaplan-Meier test, the patients in the s-WDR1-Ab-positive and s-CFL1-Ab-negative groups exhibited a significantly poorer prognosis in the overall survival analysis. On the whole, the present study demonstrates that the combination of positive anti-WDR1 antibodies with negative anti-CFL1 antibodies in serum may be a poor prognostic factor for patients with esophageal carcinoma.

JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases

“…Our findings highlighted potential biomarkers for stroke including DIDO1, CPSF2, FOXJ2, DNAJC2, ALDOA, FH4, ASXL2, AP3D1, SERPINE1, and TSTD2 [11][12][13][14][15][16][17]. Likewise, we identified LRPAP1, CFL1, WDR1, and striatin 4 as potential markers for digestive tract tumors [18][19][20][21].…”

Combination of high anti‐SKI and low anti‐TMED5 antibody levels is preferable prognostic factor in esophageal carcinoma

“…Our SEREX screening method has identified many antibody biomarkers or antigens, including trophoblast cell surface antigen 2 (TROP2), 6 solute carrier family 2 member 1/glucose transporter 1 (SLC2A1/GLUT1), 7 ZIC2, 8 BAMBI, 9 striatin, 10 LDL receptor-related protein-associated protein 1, 11 proprotein convertase subtilisin/kexin type 9, 12 cofilin, 13 and WD repeat-containing protein 1. 14 In the present study, SEREX screening for esophageal carcinoma identified the SKI proto-oncogene protein and transmembrane p24 trafficking protein 5 (TMED5). The serum anti-SKI antibody (s-SKI-Ab) and anti-TMED5 antibody (s-TMED5-Ab) levels were compared between patients with esophageal carcinoma and healthy donors (HDs).…”

“…The sequencing of isolated cDNA clones makes SEREX suitable for large‐scale screening of tumor antigens. Our SEREX screening method has identified many antibody biomarkers or antigens, including trophoblast cell surface antigen 2 (TROP2), 6 solute carrier family 2 member 1/glucose transporter 1 (SLC2A1/GLUT1), 7 ZIC2, 8 BAMBI, 9 striatin, 10 LDL receptor‐related protein‐associated protein 1, 11 proprotein convertase subtilisin/kexin type 9, 12 cofilin, 13 and WD repeat‐containing protein 1 14 …”

Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseases

“…Subsequently, the antibody levels in serum samples from patients with CVD obtained from Chiba University Hospital were examined. Given that OSAS is related to atherosclerosis and is associated with a high risk of AIS and CVD (36)(37)(38)(39), the present study also examined the sera of patients with OSAS obtained from Chiba University Hospital. Compared with those of the HDs, the s-KIAA0513-Ab levels were significantly higher in the patients with CVD or OSAS (Fig.…”

“…The anti-p53 antibody is a typical antibody biomarker for cancer that has been used in clinical practical for diagnosing, monitoring and predicting the prognosis of esophageal cancer (EC) and head and neck cancer ( 26 , 27 ). Further application of the serological identification of antigens by cDNA expression cloning and the protein array method have identified autoantibodies against tumor-associated calcium signal transducer 2( 28 ), solute carrier family 2/facilitated glucose transporter, member 1( 29 ), tripartite motif-containing 21( 30 ), myomegalin ( 31 ), makorin 1( 32 ), esophageal carcinoma SEREX antigen ( 33 ), cyclin L2( 34 ), cofilin, β-actin ( 35 ) and WD repeat-containing protein 1( 36 ) for EC; FBP-interacting repressor for colorectal cancer (CRC) ( 37 ) and gastric cancer (GC) ( 38 ); SH3 domain, GRB2-like 1( 39 ) and filamin C ( 40 ) for glioma; EP300-interacting inhibitor of differentiation 3 for non-functional pancreatic neuroendocrine tumors ( 41 ); wingless-type MMTV integration site family, member 7 for biliary cancer ( 42 ); and coatomer protein complex subunit epsilon ( 43 ), differential screening-selected gene aberrant in neuroblastoma ( 44 ), and sorting nexins 16( 45 ) for obstructive sleep apnea syndrome (OSAS). Here, we report on serum antibodies against KIAA0513 (s-KIAA0513-Ab) as a broad-spectrum biomarker applicable to atherosclerosis-related diseases such as ischemic stroke, cardiovascular disease (CVD), chronic kidney disease (CKD), DM and solid cancers.…”